Boston Scientific Corporation $BSX Shares Purchased by Simon Quick Advisors LLC

Simon Quick Advisors LLC lifted its position in Boston Scientific Corporation (NYSE:BSX) by 38.8% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 14,032 shares of the medical equipment provider’s stock after purchasing an additional 3,921 shares during the quarter. Simon Quick Advisors LLC’s holdings in Boston Scientific were worth $1,507,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Sound Income Strategies LLC boosted its position in shares of Boston Scientific by 90.9% in the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 120 shares during the period. 1248 Management LLC purchased a new position in shares of Boston Scientific during the first quarter worth about $26,000. Y.D. More Investments Ltd purchased a new position in shares of Boston Scientific during the first quarter worth about $27,000. Princeton Global Asset Management LLC purchased a new position in shares of Boston Scientific during the second quarter worth about $32,000. Finally, Migdal Insurance & Financial Holdings Ltd. grew its holdings in shares of Boston Scientific by 72.9% during the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 344 shares of the medical equipment provider’s stock worth $37,000 after buying an additional 145 shares during the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Ellen M. Zane sold 2,901 shares of Boston Scientific stock in a transaction that occurred on Tuesday, October 28th. The shares were sold at an average price of $102.24, for a total transaction of $296,598.24. Following the completion of the sale, the director directly owned 24,134 shares in the company, valued at approximately $2,467,460.16. This trade represents a 10.73% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $98.47, for a total transaction of $4,923,500.00. Following the sale, the executive vice president owned 178,342 shares of the company’s stock, valued at approximately $17,561,336.74. The trade was a 21.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 112,891 shares of company stock valued at $11,501,887. Insiders own 0.50% of the company’s stock.

Boston Scientific Stock Performance

Shares of BSX stock opened at $100.55 on Friday. The company has a market cap of $148.98 billion, a price-to-earnings ratio of 53.77, a price-to-earnings-growth ratio of 2.02 and a beta of 0.61. The stock has a 50 day simple moving average of $100.87 and a 200-day simple moving average of $102.25. Boston Scientific Corporation has a 12-month low of $83.38 and a 12-month high of $109.50. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. The business had revenue of $5.07 billion during the quarter, compared to the consensus estimate of $4.97 billion. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The company’s revenue for the quarter was up 20.3% on a year-over-year basis. During the same period in the prior year, the business posted $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. On average, equities analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on BSX shares. Evercore ISI reissued an “outperform” rating on shares of Boston Scientific in a report on Wednesday, October 22nd. Jefferies Financial Group reissued a “hold” rating on shares of Boston Scientific in a report on Monday, July 21st. Royal Bank Of Canada reissued an “outperform” rating and set a $125.00 price target on shares of Boston Scientific in a report on Monday, September 29th. Truist Financial raised their price target on Boston Scientific from $129.00 to $130.00 and gave the stock a “buy” rating in a report on Thursday, October 23rd. Finally, Wall Street Zen raised Boston Scientific from a “hold” rating to a “buy” rating in a report on Saturday, October 11th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $123.77.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.